Controversy over short-seller allegations and a lowball bid in a takeover attempt that puzzled investors. This has been rebounded off its lows but he can't accept the high valuations of these cannabis companies, some being extreme, and based on speculation.

Major assets include the 407, with the core engineering construction assets for a very low single-digit PE multiple. But SNC has perpetually disappointed through earnings misses or bad headlines. They need to win back investor confidence in their core engineering business. There's always another shoe to drop with SNC. Unpredictable.

Unpredictable and cyclical industry. He avoids steel. We're late in the cycle so it's dangerous. He prefers Stelco for its cleaner balance sheet.

Cutting production and dividend recently, but the stock price is still low. It's the ultimate contrarian pick. Something eventually will happen to revalue this stock, like somebody buys it. Cutting the dividend and paying down debt were the right decisions they've made. With crude prices rising and the WCS spread shrinking, something will eventually happen to this stock.

A well-run blue chip. The price fells after a poor Q3. But it's moving into organics and just announced a new poultry operation with a new facility in London, ON. Trades at only 8x EBITDA. Great value. Solid balance sheet. (Analysts’ price target is $38.22)

Their core P&C insurance business has improved in recent years. They now have a lot of cash. You're betting on Prem Watsa's investing acumen who will put that capital to work. Trading close to book value for the first time in six years. (Analysts’ price target is $748.46)

Poor Q3 pressured the stock, but sees secular growth in warehouse automation, healthcare equipment and e-cars (to do the automation in those factories). A healthy balance sheet. They just announced an acqusition; he expects more M&A to drive growth. Trading at a low multiple vs. history and peers. Good value here. (Analysts’ price target is $23.25)